Sight Sciences (SGHT) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Registrant Name	SIGHT SCIENCES, INC.
Entity Central Index Key	0001531177
Entity File Number	001-40587
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	80-0625749
Entity Address, Address Line One	4040 Campbell Ave
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Menlo Park
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94025
City Area Code	877
Local Phone Number	266-1144
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	SGHT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		47,307,477

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 271,475	$ 61,511
Accounts receivable, net	8,920	5,363
Inventory, net	2,948	2,598
Prepaid expenses and other current assets	4,493	1,161
Total current assets	287,836	70,633
Property and equipment, net	1,420	1,269
Operating lease right-of-use assets	1,612	518
Other noncurrent assets	182	386
Total assets	291,050	72,806
Current liabilities:
Accounts payable	1,839	2,158
Accrued compensation	4,639	4,070
Accrued and other current liabilities	3,837	3,086
Total current liabilities	10,315	9,314
Long-term debt	32,486	31,955
Other noncurrent liabilities	2,273	3,055
Total liabilities	45,074	44,324
Commitments and contingencies (Note 6)
Stockholders' equity (deficit):
Common stock par value of $0.001 per share; 200,000,000 and 21,831,000 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 47,292,022 and 9,509,182 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	49	9
Additional paid-in-capital	382,992	1,183
Accumulated deficit	(137,065)	(90,041)
Total stockholders' equity (deficit)	245,976	(88,849)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	291,050	72,806
Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Convertible preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2021, no shares issued and outstanding as of September 30, 2021; 14,241,390 shares authorized as of December 31, 2020, 12,767,202 shares issued and outstanding as of December 31, 2020; aggregate liquidation preference of $118.6 million as of December 31, 2020	$ 0	$ 117,331

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Convertible preferred stock, shares issued		12,767,202
Convertible preferred stock, shares outstanding		12,767,202
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	21,831,000
Common stock, shares issued	47,292,022	9,509,182
Common stock, shares outstanding	47,292,022	9,509,182
Redeemable Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	10,000,000	14,241,390
Convertible preferred stock, shares issued	0	12,767,202
Convertible preferred stock, shares outstanding	0	12,767,202
Convertible preferred stock, aggregate liquidation preference		$ 118,626

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 13,101	$ 8,651	$ 34,271	$ 18,649
Cost of goods sold	2,062	2,620	6,668	6,833
Gross profit	11,039	6,031	27,603	11,816
Operating expenses:
Research and development	4,279	2,158	11,265	6,001
Selling, general and administrative	20,790	11,228	53,100	29,570
Total operating expenses	25,069	13,386	64,365	35,571
Loss from operations	(14,030)	(7,355)	(36,762)	(23,755)
Interest income		1		30
Interest expense	(1,122)	(538)	(3,288)	(1,639)
Other expense, net	(2,001)	(197)	(6,884)	179
Loss before income taxes	(17,153)	(8,089)	(46,934)	(25,543)
Provision for income taxes	16	8	90	45
Net loss and comprehensive loss	$ (17,169)	$ (8,097)	$ (47,024)	$ (25,588)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.43)	$ (0.85)	$ (2.38)	$ (2.70)
Weighted-average shares outstanding, basic and diluted	39,849,769	9,493,548	19,772,145	9,467,039

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	IPO	Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred StockIPO	Common Stock	Common StockIPO	Additional Paid-In Capital	Additional Paid-In CapitalIPO	Accumulated Deficit
Beginning Balance at Dec. 31, 2019			$ 64,256
Beginning Balance, shares at Dec. 31, 2019			9,804,640
Beginning Balance at Dec. 31, 2019	$ (54,683)				$ 9		$ 656		$ (55,348)
Beginning Balance, shares at Dec. 31, 2019					9,319,466
Issuance of Series E convertible preferred stock	0		$ 30,055
Issuance of Series E convertible preferred stock, shares			1,899,847
Exercise of stock options	1						1
Exercise of stock options, shares					1,500
Stock-based compensation expense	61						61
Net loss and comprehensive loss	(9,175)								(9,175)
Ending Balance at Mar. 31, 2020			$ 94,311
Ending Balance, shares at Mar. 31, 2020			11,704,487
Ending Balance at Mar. 31, 2020	(63,796)				$ 9		718		(64,523)
Ending Balance, shares at Mar. 31, 2020					9,320,966
Beginning Balance at Dec. 31, 2019			$ 64,256
Beginning Balance, shares at Dec. 31, 2019			9,804,640
Beginning Balance at Dec. 31, 2019	(54,683)				$ 9		656		(55,348)
Beginning Balance, shares at Dec. 31, 2019					9,319,466
Net loss and comprehensive loss	(25,588)
Ending Balance at Sep. 30, 2020			$ 94,244
Ending Balance, shares at Sep. 30, 2020			11,704,487
Ending Balance at Sep. 30, 2020	(79,960)				$ 9		967		(80,936)
Ending Balance, shares at Sep. 30, 2020					9,375,832
Beginning Balance at Mar. 31, 2020			$ 94,311
Beginning Balance, shares at Mar. 31, 2020			11,704,487
Beginning Balance at Mar. 31, 2020	(63,796)				$ 9		718		(64,523)
Beginning Balance, shares at Mar. 31, 2020					9,320,966
Issuance of Series E convertible preferred stock	0		$ 12
Exercise of stock options	7						7
Exercise of stock options, shares					20,520
Stock-based compensation expense	65						65
Net loss and comprehensive loss	(8,316)								(8,316)
Ending Balance at Jun. 30, 2020	(72,040)		$ 94,299		$ 9		790		(72,839)
Ending Balance, shares at Jun. 30, 2020			11,704,487		9,341,486
Series F redeemable convertible preferred stock issuance cost	0		$ (55)
Exercise of stock options	12						12
Exercise of stock options, shares					34,346
Stock-based compensation expense	165						165
Net loss and comprehensive loss	(8,097)								(8,097)
Ending Balance at Sep. 30, 2020			$ 94,244
Ending Balance, shares at Sep. 30, 2020			11,704,487
Ending Balance at Sep. 30, 2020	$ (79,960)				$ 9		967		(80,936)
Ending Balance, shares at Sep. 30, 2020					9,375,832
Beginning Balance at Dec. 31, 2020			$ 117,331
Beginning Balance, shares at Dec. 31, 2020	12,767,202		12,767,202
Beginning Balance at Dec. 31, 2020	$ (88,849)				$ 9		1,183		(90,041)
Beginning Balance, shares at Dec. 31, 2020					9,509,182
Exercise of stock options	11						11
Exercise of stock options, shares					16,862
Stock-based compensation expense	277						277
Net loss and comprehensive loss	(12,240)								(12,240)
Ending Balance at Mar. 31, 2021			$ 117,331
Ending Balance, shares at Mar. 31, 2021			12,767,202
Ending Balance at Mar. 31, 2021	$ (100,801)				$ 9		1,471		(102,281)
Ending Balance, shares at Mar. 31, 2021					9,526,044
Beginning Balance at Dec. 31, 2020			$ 117,331
Beginning Balance, shares at Dec. 31, 2020	12,767,202		12,767,202
Beginning Balance at Dec. 31, 2020	$ (88,849)				$ 9		1,183		(90,041)
Beginning Balance, shares at Dec. 31, 2020					9,509,182
Conversion of redeemable convertible preferred stock	25,534,404
Net loss and comprehensive loss	$ (47,024)
Ending Balance at Sep. 30, 2021			$ 0
Ending Balance, shares at Sep. 30, 2021			0
Ending Balance at Sep. 30, 2021	245,976				$ 49		382,992		(137,065)
Ending Balance, shares at Sep. 30, 2021					47,292,022
Beginning Balance at Mar. 31, 2021			$ 117,331
Beginning Balance, shares at Mar. 31, 2021			12,767,202
Beginning Balance at Mar. 31, 2021	(100,801)				$ 9		1,471		(102,281)
Beginning Balance, shares at Mar. 31, 2021					9,526,044
Exercise of stock options	196						196
Exercise of stock options, shares					205,988
Stock-based compensation expense	931						931
Net loss and comprehensive loss	(17,615)								(17,615)
Ending Balance at Jun. 30, 2021			$ 117,331
Ending Balance, shares at Jun. 30, 2021			12,767,202
Ending Balance at Jun. 30, 2021	(117,289)				$ 9		2,598		(119,896)
Ending Balance, shares at Jun. 30, 2021					9,732,032
Conversion of redeemable convertible preferred stock to common stock upon initial public offering		$ 117,331		$ (117,331)		$ 27		$ 117,304
Conversion of redeemable convertible preferred stock				(12,767,202)		25,534,404
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs of $23.8 million	252,174				$ 12		252,162
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs of $23.8 million, shares					11,500,000
Conversion of redeemable convertible preferred stock warrants to common stock warrants upon initial public offering		$ 8,973						$ 8,973
Exercise of common stock warrants	0				$ 1		(1)
Exercise of common stock warrants, shares					483,554
Exercise of stock options	57						57
Exercise of stock options, shares					42,032
Stock-based compensation expense	1,899						1,899
Net loss and comprehensive loss	(17,169)								(17,169)
Ending Balance at Sep. 30, 2021			$ 0
Ending Balance, shares at Sep. 30, 2021			0
Ending Balance at Sep. 30, 2021	$ 245,976				$ 49		$ 382,992		$ (137,065)
Ending Balance, shares at Sep. 30, 2021					47,292,022

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2021	Mar. 31, 2020
IPO
Issuance costs	$ 23.8
Series E Convertible Preferred Stock
Issuance costs		$ 94

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (47,024,000)	$ (25,588,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	457,000	418,000
Accretion of debt discount and amortization of debt issuance costs	531,000	421,000
Stock-based compensation expense	3,107,000	291,000
Provision for doubtful accounts receivable	149,000	188,000
Provision for excess and obsolete inventories	297,000	1,093,000
Amortization of right-of-use asset	448,000	414,000
Change in fair value of redeemable convertible preferred stock warrant	6,861,000	175,000
Loss on disposal of property and equipment	(98,000)	121,000
Proceeds from Paycheck Protection Program loan		(2,246,000)
Changes in operating assets and liabilities:
Accounts receivable	(3,707,000)	(1,170,000)
Inventory	(648,000)	(1,106,000)
Prepaid expenses and other current assets	(3,331,000)	(421,000)
Other noncurrent assets	204,000	130,000
Accounts payable	(319,000)	(104,000)
Accrued compensation	569,000	634,000
Accrued and other current liabilities	211,000	2,368,000
Other noncurrent liabilities	279,000	758,000
Net cash used in operating activities	(41,818,000)	(23,624,000)
Cash flows from investing activities
Purchases of property and equipment	(656,000)	(651,000)
Net cash used in investing activities	(656,000)	(651,000)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions	256,680,000
Payment of other offering costs related to the initial public offering
Debt issuance costs - third party		(126,000)
Proceeds from the issuance of redeemable convertible preferred stock		30,150,000
Redeemable convertible preferred stock issuance cost		(161,000)
Proceeds from exercise of common stock options	264,000	19,000
Net cash (used in) provided by financing activities	252,438,000	29,882,000
Net change in cash and cash equivalents	209,964,000	5,607,000
Cash and cash equivalents at beginning of period	61,511,000	21,237,000
Cash and cash equivalents at end of period	271,475,000	26,844,000
Supplemental disclosure of cash flow information
Cash paid for interest	2,331,000	936,000
Supplemental noncash disclosure
Acquisition of property and equipment included in accounts payable and accrued liabilities	83,000	123,000
Noncash investing and financing:
Common Stock issued on conversion of convertible preferred stock	117,331,000
Common stock warrants issued on conversion of preferred stock warrants and the reclassification of the warrant liability	$ 8,973,000

Company and Nature of Business

Company and Nature of Business	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	Note 1. Company and Nature of Business Description of Business Sight Sciences, Inc. (the “Company”) was incorporated in the State of Delaware in 2010. The Company is located and headquartered in Menlo Park, California and has its principal commercial offices in Southlake, Texas. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI® Surgical System, a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. The Company’s nonsurgical dry eye product portfolio consists of the TearCare® System ("TearCare") for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. Stock Split On July 7, 2021 the Company effected a 2-for-1 stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the redeemable convertible preferred stock conversion ratios. Initial Public Offering On July 19, 2021, the Company closed its initial public offering (“IPO”) of its common stock in which the Company issued and sold 10,000,000 shares of its common stock, and sold an additional 1,500,000 shares of common stock upon the full exercise of the underwriters’ option to purchase additional shares of the Company's common stock. These sales occurred at the initial public offering price of $ 24.00 per share. The Company received net proceeds of approximately $ 252.2 million from the IPO, after deducting underwriting discounts and commissions of $ 19.3 million and offering costs of $ 4.5 million, of which $ 0.4 million were incurred as of December 31, 2020. Immediately prior to the closing of the IPO, all then-outstanding shares of redeemable convertible preferred stock were converted into 25,534,404 shares of common stock. Further, all outstanding redeemable convertible preferred stock warrants were converted into warrants to purchase 659,028 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liability to additional paid-in capital. In connection with the Company’s IPO, in July 2021, the Company’s certificate of incorporation was amended and restated to provide for 200,000,000 authorized shares of common stock with a par value of $ 0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $ 0.001 per share. Significant Risks and Uncertainties Since inception, the Company has incurred losses and negative cash flows from operations. As of September 30, 2021, the Company had an accumulated deficit of $ 137.1 million and recorded a net loss of $ 47.0 million for the nine months then ended and expects to incur future additional losses. If the Company’s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products and scale back its business and operations. The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its financial statements. Failure to generate sufficient revenues, achieve planned gross margins, or control operating costs will require the Company to raise additional capital through equity or debt financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives. On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (“COVID-19”) outbreak a global pandemic recommending containment measures worldwide. On March 16, 2020 the Company implemented alternative work arrangements for its employees and limited its employees’ travel activities to protect its employees and to comply with the provisions described within the local shelter in place order. Certain U.S. federal, state and local governmental authorities issued other orders and directives, including restrictions on elective procedures and therapies, aimed at minimizing the spread of COVID-19. As such, the COVID-19 pandemic impacted and is expected to continue to impact demand for the Company’s products, which are used in procedures and therapies that are considered elective. Although some of the governmental restrictions have since been lifted or scaled back, recent and future surges of COVID-19, including recent surges in the delta variant of COVID-19, may result in restrictions being re-implemented in response to efforts to reduce the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the COVID-19 outbreak (including prevalence and effect of the delta variant and other potential COVID-19 variants), the status of health and safety actions taken to contain its spread and any additional preventative and protective actions that governments or the Company may direct, any resurgence of COVID-19 that may occur and how quickly and to what extent economic and operating conditions normalize within the markets in which the Company operates. The COVID-19 pandemic could disrupt the operations of the Company’s third-party manufacturers and other suppliers. Although the Company has not experienced material disruptions in its supply chain to date, it cannot predict how long the pandemic and measures intended to contain the spread of COVID-19 will continue and what effect COVID-19 and the associated containment measures will have on our suppliers and vendors, in particular for any of the Company’s suppliers and vendors that may not qualify as essential businesses and suffer more significant disruptions to their business operations. The Company is working closely with its manufacturing partners and suppliers to help ensure the Company is able to source key components and maintain appropriate inventory levels to meet customer demand.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) applicable to interim periods. The condensed consolidated financial statements, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the Company’s financial position and results of operations for the reported periods. These condensed consolidated financial statements have been prepared on a basis substantially consistent with, and should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto included in the prospectus, dated July 14, 2021, filed with the Securities and Exchange Commission ("SEC") in accordance with Rule 424(b) of the Securities Act on July 15, 2021 (the "Prospectus") in connection with our IPO that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-257320), as filed with the SEC pursuant to Rule 424(b)(4) promulgated under the Securities Act. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with GAAP have been condensed or omitted from this report. The results of operations for any interim period are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period. The accompanying condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to inventory excess and obsolescence, the selection of useful lives of property and equipment, determination of the fair value of stock option grants, the fair value of the redeemable convertible preferred stock warrants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Company’s financial position and results of operations. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, redeemable convertible preferred stock, short-term and long-term debt and redeemable convertible preferred stock warrant liability. The Company states accounts receivable, accounts payable, and accrued and other current liabilities at their carrying value, which approximates fair value due to the short time to the expected receipt or payment. The carrying amount of the Company’s debt approximates its fair value as the effective interest rate approximates market rates currently available to the Company. The redeemable convertible preferred stock warrant liability associated with the Company’s redeemable convertible preferred stock was carried at fair value based on unobservable market inputs. The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in July 2021. At that time, the preferred stock warrant liability was adjusted to fair value and reclassified to additional paid-in capital (see Note 3). Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s IPO, were deferred until completion of the IPO. As of December 31, 2020, deferred offering costs of $ 0.4 million were capitalized and are included in “Other noncurrent assets”. In July 2021, upon closing of the IPO, total deferred costs of $ 4.5 million were offset against the Company's IPO proceeds in additional paid in capital. Accounting for Payroll Protection Program In March 2020, Congress established the Paycheck Protection Program (“PPP”) to provide relief to small businesses during COVID-19 as part of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The legislation authorized the U.S. Treasury to use the Small Business Association’s (“SBA’s”) small business lending program to fund forgivable loans that qualifying businesses could spend to cover payroll, mortgage interest, rent, and utilities during the “Covered Period” defined as the 8-week period starting on the date the PPP loan proceeds are received. Upon meeting certain criteria as specified in the PPP program, the loans are eligible for partial or total forgiveness. In May 2020, the Company applied for and received a PPP loan for the amount $ 2.2 million from SBA. The PPP loan was forgiven in June 2021. GAAP does not contain authoritative accounting standards for forgivable loans provided by governmental entities to a for-profit entity. Absent authoritative accounting standards, interpretative guidance issued and commonly applied by financial statement preparers allows for the selection of accounting policies amongst acceptable alternatives. The Company determined it most appropriate to account for the PPP loan proceeds as an in-substance government grant by analogy to International Accounting Standards 20 (“IAS 20”) Accounting for Government Grants and Disclosure of Government Assistance . Under this guidance, a forgivable loan from government is treated as a government grant when there is reasonable assurance that the entity will meet the terms for forgiveness of the loan. While IAS 20 does not define “reasonable assurance”, this concept in practice is analogous to “probable” as defined in Financial Accounting Standards Board (“FASB”) ASC 450-20-20 under GAAP, which is the definition the Company applied to its expectations of PPP loan forgiveness. Under IAS 20, government grants are recognized in earnings on a systematic basis over the periods in which the Company recognizes costs for which the grant is intended to compensate (i.e. qualified expenses). Further, IAS 20 permits for the recognition in earnings either separately under a general heading such as other income, or as a reduction of the related expenses. New Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The guidance is effective for the Company beginning in the first quarter of 2023. The Company is evaluating the impact of adopting this guidance and does not expect to have a material impact on the Company’s financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , that simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation and modified the methodology for calculating income taxes in an interim period. It also clarifies and simplifies other aspects of the accounting for income taxes. The guidance is effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022 with early adoption permitted. The Company is evaluating the effect of this new guidance and does not expect it to have material impact on the Company’s financial statements. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The guidance also establishes (1) a general contract modification principle that entities can apply in other areas that may be affected by reference rate reform and (2) certain elective hedge accounting expedients. The amendment is effective for all entities through December 31, 2022. LIBOR is used to calculate the interest on borrowings under the Company’s term loan and revolving line of credit with MidCap Financial Services. The Company is evaluating the effect of this new guidance and does not expect it to have material impact on the Company’s financial statements.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 3. Fair Value Measurements The Company reports all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3—Inputs are unobservable inputs for the asset or liability. The level in the fair value hierarchy within which a fair value measurement in its entirety is based on the lowest-level input that is significant to the fair value measurement in its entirety. The financial statements as of September 30, 2021 and December 31, 2020, do not include any nonrecurring fair value measurements relating to assets or liabilities. The following table sets forth the fair value measurements of liabilities that are measured at fair value on a recurring basis as of December 31, 2020 (in thousands). As of September 30, 2021, there were no liabilities that are measured at fair value on a recurring basis. As of December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities: Redeemable convertible preferred stock warrants liabilities $ — $ — $ 2,112 $ 2,112 Total liabilities measured at fair value $ — $ — $ 2,112 $ 2,112 The Company measures the redeemable convertible preferred stock warrants using Level 3 unobservable inputs within the Black-Scholes option-pricing model. The key assumptions include the fair value of redeemable convertible preferred stock, volatility, the risk-free interest rate, expected term (remaining contractual term of the warrants) and dividend yield. The Company has limited historical volatility information available, and the expected volatility was based on actual volatility for comparable public companies projected over the expected terms of the warrants. The Company did not apply a forfeiture rate to the warrants as there is not enough historical information available to estimate such a rate. The risk-free interest rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the warrants. Refer to Note 9 for the assumptions used. The Company measures the fair value of outstanding debt for disclosure purposes on a recurring basis. As of September 30, 2021 and December 31, 2020, total debt of $ 32.5 million and $ 31.9 million is reported at amortized cost, respectively. This outstanding debt is classified as Level 2 as it is not actively traded. The amortized cost of the outstanding debt approximates the fair value. The Company determines the fair value of the redeemable convertible preferred stock warrants quarterly, with subsequent gains and losses from remeasurement of Level 3 financial liabilities recorded through other income (expense), net in condensed statements of operations and comprehensive loss. A summary of the changes in the fair value of the Company’s Level 3 financial instruments for the three and nine months ended September 30, 2021 and 2020, is as follows (in thousands): Redeemable convertible preferred stock warrants liabilities Balance – December 31, 2020 $ 2,112 Change in fair value ( 555 ) Balance – March 31, 2021 1,557 Change in fair value 5,427 Balance – June 30, 2021 6,984 Change in fair value 1,989 Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO ( 8,973 ) Balance – September 30, 2021 $ — Redeemable convertible preferred stock warrants liabilities Balance – December 31, 2019 $ 236 Change in fair value ( 92 ) Balance – March 31, 2020 144 Change in fair value 73 Balance – June 30, 2020 217 Change in fair value 194 Balance – September 30, 2020 $ 411

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Components	Note 4. Balance Sheet Components Property and Equipment, Net Property and equipment, net consist of the following (in thousands): As of September 30, As of December 31, 2021 2020 Tools and equipment $ 1,720 $ 1,523 Computer equipment and software 108 118 Furniture and fixtures 254 43 Leasehold improvements 29 30 Construction in process 393 298 2,504 2,012 Less: Accumulated depreciation ( 1,084 ) ( 743 ) Property and equipment, net $ 1,420 $ 1,269 Depreciation expense was $ 0.2 million and $ 0.5 million for the three and nine months ended September 30, 2021, respectively. Depreciation expense was $ 0.1 million and $ 0.4 million for the three and nine months ended September 30, 2020, respectively. Accrued and Other Current Liabilities Accrued and other current liabilities consist of the following (in thousands): As of September 30, As of December 31, 2021 2020 Accrued expenses $ 2,569 $ 1,971 Current portion of lease liabilities 486 395 Short term interest payable 272 274 Other accrued liabilities 510 446 Total accrued and other current liabilities $ 3,837 $ 3,086 Other Noncurrent Liabilities Other noncurrent liabilities consist of the following (in thousands): As of September 30, As of December 31, 2021 2020 Redeemable preferred stock warrants liabilities $ — $ 2,112 Long term interest payable 750 465 Noncurrent portion of lease liabilities 1,178 134 Other noncurrent liabilities 345 344 Total other noncurrent liabilities $ 2,273 $ 3,055

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	Note 5. Debt In January 2019, the Company entered into credit and security agreements with MidCap Financial Services, or the Lender, which provided a maximum of $ 25.0 million credit facility consisting of a $ 20.0 million senior secured term loan (the "2019 Term Loan") and a $ 5.0 million 2019 revolving loan (the "2019 Revolver" and collectively with the 2019 Term Loan, the “2019 MidCap Credit Facility”). In November 2020, the Company entered into amended and restated credit and security agreements with the same institution, which replaced the 2019 MidCap Credit Facility, and provided for a maximum of $ 40.0 million credit facility consisting of a $ 35.0 million senior secured term loan (the "2020 Term Loan") and a $ 5.0 million revolving loan (the "2020 Revolver and collectively with the 2020 Term Loan, the “2020 MidCap Credit Facility”). 2019 Term Loan The 2019 Term Loan had a four-year term and had a stated floating interest rate which equates to reserve- adjusted LIBOR + 6.75 %. The 2019 Term Loan was split into three tranches as follows: (i) the Tranche One Loans provided for $ 12.0 million in term loans, (ii) the Tranche Two Loans provided for up to $ 2.0 million in term loans, and (iii) the Tranche Three Loans provided for up to $ 6.0 million in term loans. The Company borrowed $ 14.0 million under the Tranche One Loans and Tranche Two Loans. While the conditions necessary to draw the Tranche Three Loans had been met as of December 31, 2019, the Company did not elect to draw the Tranche Three Loans. The 2019 Term Loan originally required 18 monthly interest-only payments , which began on January 31, 2019, followed by 30 equal monthly installments of principal, plus interest. The interest-only period was extended by an additional six months upon achievement of the Tranche Three Milestone. The 2019 Term Loan had an effective interest rate of 14.52 % per year. The 2019 Term Loan interest expense for the three months ended September 30, 2021 and 2020 was $ 0.0 and $ 0.5 million, respectively. The 2019 Term Loan interest expense for the nine months ended September 30, 2021 and 2020 was $ 0.0 and $ 1.6 million, respectively. In conjunction with the funding of Tranche One Loans and Tranche Two Loans under the 2019 Term Loan, the Company issued a 10-year warrant to the Lender to purchase 29,514 shares of the Company’s Series C redeemable convertible preferred stock (the “2019 Initial Warrant”) at an exercise price of $ 9.49 per share (the “Exercise Price”). Further, depending on the funding of the Tranche Three Loans, the Company was obligated to issue an additional Warrant to the Lender to purchase up to 12,649 shares of Series C redeemable convertible preferred stock at the Exercise Price (the “2019 Additional Warrant” and together with “2019 Initial Warrant” the “2019 Warrants”) (see Note 9). The conditions precedent to issuance of the 2019 Additional Warrant were never satisfied, so the warrant was not issued, and the Company's prospective obligation to issue the 2019 Additional Warrant expired upon modification of the 2019 Term Loan. In August 2021, the Lender effected a net exercise in full of the 2019 Initial Warrant and the Company issued the Lender 51,846 shares of common stock. The estimated fair value of the 2019 Warrants of $ 0.2 million upon draw down was based on the Black- Scholes option-pricing model and probability of future draw downs. The 2019 Warrants were recorded at the fair value as a debt discount and as a warrant liability. The debt discount was being accreted using the effective interest method as interest expense over the contractual period of four years for the 2019 Term Loan. The Company incurred $ 1.5 million of issuance costs in conjunction with the 2019 Term Loan. The issuance costs were netted against the borrowed funds in the condensed consolidated balance sheet and were accreted using the effective interest method as interest expense over the contractual period of four years for the 2019 Term Loan. The Company could voluntarily prepay the 2019 Term Loan borrowings in full, with a prepayment premium beginning at 3 % in the first year from tranche funding, to 2 % in the second year from tranche funding, to 1 % in the third year from tranche funding thereafter. In addition, a final payment fee of 5 % of the amounts borrowed was payable at the end of the term or when the borrowings were repaid in full. A long-term liability was being accreted using the effective interest method for the final payment fee over the term of the loan agreement. The borrowings were collateralized by a security interest in substantially all of the Company’s assets. The Company was subject to financial covenants related to minimum trailing revenue targets that began on January 1, 2019, and were tested on a monthly basis. Upon funding of only the Tranche One Loans, the Company had to achieve minimum net revenue of $ 7 million over a trailing 12-month period increasing to a maximum net revenue covenant of $ 35 million for the trailing 12-month period ending December 31, 2022, and thereafter. Upon funding of both the Tranche One Loans and Tranche Two Loans, the Company had to achieve minimum net revenue of $ 7 million over a trailing 12-month period increasing to a maximum net revenue covenant of $ 37.3 million for the 12-month period ending December 31, 2022, and thereafter. If Tranche Three Loans had been funded regardless of whether Tranche Two Loans had been funded, the Company would have been required to achieve minimum net revenue of $ 15 million over a trailing 12-month period increasing to a maximum net revenue covenant of $ 46.7 million for the 12-month period ending December 31, 2022, and thereafter. On November 23, 2020, the 2019 Term Loan was replaced with 2020 Term Loan (see below). 2019 Revolver The 2019 Revolver had a four-year term and has a stated floating interest rate which equates to reserve- adjusted LIBOR plus 4.25 %. An unused line fee of 0.5 % was payable monthly based on the average unused balance and a collateral management fee of 0.5 % was payable monthly based on the outstanding balance of the 2019 Revolver. The Company could request to increase the 2019 Revolver commitment amount to $ 10.0 million under the term of the agreement. On November 23, 2020, the 2019 Revolver was replaced with the 2020 Revolver (see below). 2020 Term Loan The 2020 Term Loan has a five-year term and has a stated floating interest rate which equates to reserve- adjusted LIBOR + 7.00 %. The 2020 Term Loan is split into three tranches as follows: (i) the Tranche One Loans provide for $ 12.0 million in term loans which are deemed to have been converted from Tranche One Loans that were drawn and outstanding under the 2019 Term Loan immediately prior to entering into 2020 MidCap Credit Facility, (ii) the Tranche Two Loans provided for up to $ 2.0 million in term loans which are deemed to have been converted from Tranche Two Loans that were drawn and outstanding under the 2019 Term Loan immediately prior to entering into 2020 MidCap Credit Facility, and (iii) the Tranche Three Loans provided for up to $ 21.0 million in new term loans. The Company borrowed $ 21.0 million under the Tranche Three Loans in November 2020. The 2020 Term Loan requires 24 monthly interest-only payments, which began on December 1, 2020, followed by 36 equal monthly installments of principal, plus interest. The interest-only period can be extended by an additional 12 months provided that the Company is in compliance with the minimum trailing revenue targets (as described below), and has unrestricted cash and cash equivalents of at least 12 times of the amortization monthly cash burn amount, measured as defined in the 2020 Term Loan agreement (“First IO Extension”). If the First IO Extension conditions are satisfied, the interest-only period can be further extended by an additional 12 months, provided that the Company is in compliance with the minimum trailing revenue targets (as described below), has unrestricted cash and cash equivalents of at least 12 times of the amortization monthly cash burn amount, and has consummated an IPO in which the Company has received cash proceeds of at least $ 60.0 million. The 2020 Term Loan has an effective interest rate of 13.59 % per year. The 2020 Term Loan interest expense for the three months ended September 30, 2021 and 2020 was $ 1.1 million and $ 0.0 , respectively. The 2020 Term Loan interest expense for the nine months ended September 30, 2021 and 2020 was $ 3.3 million and $ 0.0 , respectively. In conjunction with entry into the 2020 MidCap Credit Facility, the Company issued a 10-year warrant to the Lender to purchase 300,000 shares of the Company’s Series F redeemable convertible preferred stock (the “2020 Warrant”) at an exercise price of $ 21.88 per share (see Note 9). The estimated fair value at issuance of the 2020 Warrant of $ 1.8 million was based on the Option-Pricing Method with Discounts for Lack of Marketability for each class of security. In addition, the Company incurred $ 0.5 million of issuance costs paid to the Lender in conjunction with the 2020 Term Loan which represents a debt discount. The Company concluded that the 2020 Term Loan represented a modification of the 2019 Term Loan and accounted for the 2020 Term Loan as debt modification. The 2020 Warrant was recorded at the fair value as a debt discount and as a warrant liability. At each balance sheet date, the 2020 Warrant was remeasured to fair value with any changes in fair value recognized as other income or expense in the statements of operations. The debt discount is being amortized using the effective interest method as interest expense over the contractual period of five years for the 2020 Term Loan. In August 2021, the Lender effected a net exercise in full of the 2020 Warrant and the Company issued the Lender 431,708 shares of common stock. The Company can voluntarily prepay the borrowings in full, with a prepayment premium beginning at 3 % in the first year from entering into the 2020 MidCap Credit facility and declining to 2 % in the second year to 1 % in the third year thereafter. In addition, a final payment fee of 6 % of the amounts borrowed is payable at the end of the term or when the borrowings are repaid in full. A long-term liability is being accreted using the effective interest method for the final payment fee over the term of the loan agreement. The borrowings are collateralized by a security interest in substantially all of the Company’s assets. The Company accrued $ 0.8 million and $ 0.5 million as of September 30, 2021 and December 31, 2020, respectively, related to accretion of final payment due at maturity per the agreement using the effective interest rate method. The final payment accrual is recorded in Other noncurrent liabilities on the balance sheets. The Company is subject to financial covenants related to minimum trailing revenue targets that began on September 30, 2020 and are tested on a monthly basis. The Company has to achieve minimum net revenue of $ 20.0 million over a trailing 12-month period increasing to a maximum net revenue covenant of $ 84.8 million for the trailing 12-month period ending October 31, 2025. As of September 30, 2021, the Company was in compliance with the applicable financial covenant. 2020 Revolver The 2020 Revolver has a four-year term and has a stated floating interest rate which equates to reserve- adjusted LIBOR plus 4.50 %. An unused line fee of 0.5 % is payable monthly based on the average unused balance and a collateral management fee of 0.5 % is payable monthly based on the outstanding balance of the 2020 Revolver. The Company can request to increase the 2020 Revolver commitment amount to $ 15.0 million under the term of the agreement. As of September 30, 2021, $ 5.0 million was available to be drawn under the 2020 Revolver. The 2020 Revolver has not been drawn upon as of September 30, 2021. Long-term and short-term debt was as follows (in thousands): As of September 30, As of December 31, 2021 2020 Term Loan $ 35,000 $ 35,000 Total principal payments due 35,000 35,000 Less: debt discount related to warrant liability and issuance costs ( 2,514 ) ( 3,045 ) Total amounts outstanding 32,486 31,955 Less: Current portion — — Total accrued and other current liabilities $ 32,486 $ 31,955 The repayment schedule relating to the Company’s debt as of September 30, 2021, is as follows (in thousands): Amount 2021 (remainder) — 2022 ( 1,944 ) 2023 ( 11,667 ) 2024 ( 11,667 ) 2025 ( 9,722 ) Total repayments $ ( 35,000 )

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies Operating Lease Obligations The Company’s leases mainly include facility leases and storage leases. In September 2019, the Company entered into a noncancelable operating lease for approximately 10,823 square feet of primary office space, which expired on July 31, 2021 , without the option to extend. On February 5, 2021, the Company entered into a lease to renew the corporate headquarters in Menlo Park, California. The lease commenced on August 1, 2021 and is for a term of 37 months from the commencement date. The Company recorded an aggregate right-of-use ("ROU") asset and lease liability of $ 1.5 million. The ROU asset and corresponding lease liability were estimated using a weighted-average incremental borrowing rate of 13.59 %. Total base rent is approximately $ 1.6 million under the lease agreement. The Company recognizes rent expense on a straight-line basis over the noncancelable lease term. The Company’s rent expense was $ 0.2 million and $ 0.2 million for the three months ended September 30, 2021 and 2020, respectively. The Company’s rent expense was $ 0.5 million for the nine months ended September 30, 2021 and 2020. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. At the date of adoption of Topic 842, the Company determined the amounts of lease liability using a discount rate of 16.4 %, which represents the Company’s incremental borrowing rate, which was based on the Company’s current borrowing rate adjusted for various factors including level of collateralization and term. As of September 30, 2021, the remaining lease term for the lease was 2.9 years. Operating lease expense and supplemental cash flow information related to operating leases for the three and nine months ended September 30, 2020 and 2021 were as follows (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating lease expense $ 175 $ 175 $ 528 $ 488 Cash paid for operating leases 131 173 484 517 New operating lease assets obtained in exchange for 1,514 — 1,537 — During the three and nine months ended September 30, 2021 and 2020, the Company’s costs related to short-term lease arrangements and non-lease variable payments were immaterial. Aggregate future minimum lease payments at September 30, 2021 and December 31, 2020, under these noncancelable operating leases were as follows (in thousands): As of September 30, As of December 31, 2021 2020 2021 $ 170 $ 440 2022 691 66 2023 705 68 2024 462 29 Total future minimum lease payments $ 2,028 603 Less: imputed interest ( 364 ) ( 74 ) Present value of future minimum lease payments $ 1,664 529 Less: current portion of operating lease liability ( 486 ) ( 395 ) Operating lease liabilities - noncurrent $ 1,178 $ 134 Legal Proceedings On September 16, 2021, the Company filed suit in the U.S. District Court for the District of Delaware (C.A. No. 1:21-cv-01317) alleging that Ivantis, Inc. directly or indirectly infringes U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 by making, using, selling, and offering for sale the Hydrus® Microstent. The Company’s Complaint seeks money damages and injunctive relief. Ivantis has not yet responded to the Complaint, and no trial date has been set. The Company is presently unable to predict the outcome of this lawsuit or to reasonably estimate the potential financial impact of the lawsuit on the Company, if any. The Company is subject to claims and assessments from time to time in the ordinary course of business. Accruals for litigation and contingencies are reflected in the financial statements based on management’s assessment, including the advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings, and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential losses from any claims or legal proceedings are considered probable and the amounts can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount can be reasonably estimated. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period. As of September 30, 2021 and December 31, 2020, the Company was not involved in any material legal proceedings except as described above. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of September 30, 2021 and December 31, 2020.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2021
Redeemable Convertible Preferred Stock [Abstract]
Redeemable Convertible Preferred Stock	Note 7. Redeemable Convertible Preferred Stock The Company has the following redeemable convertible preferred stock issued and outstanding at December 31, 2020 (in thousands, except share and per share data): Shares Authorized Shares Issued and Outstanding Original Issuance Price Liquidation Amount Issuance Costs Carrying Value Series A 3,804,344 3,804,344 $ 1.38 $ 5,250 $ 9 $ 5,241 Series B 1,209,621 1,209,621 $ 5.79 7,000 106 6,894 Series C 2,372,371 2,342,857 $ 9.49 22,226 208 22,018 Series D 2,507,720 2,447,818 $ 12.56 30,750 647 30,103 Series E 1,921,902 1,899,847 $ 15.87 30,150 106 30,044 Series F 2,425,432 1,062,715 $ 21.88 23,250 219 23,031 14,241,390 12,767,202 $ 118,626 $ 1,295 $ 117,331 Immediately prior to the closing of the IPO, all then-outstanding shares of redeemable convertible preferred stock were converted into 25,534,404 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock of $ 117.3 million to common stock and APIC. There was no redeemable convertible preferred stock outstanding as of September 30, 2021.

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2021
Warrants And Rights Note Disclosure [Abstract]
Common Stock Warrants	Note 8. Common Stock Warrants In connection with the issuance of the Company’s Series A redeemable convertible preferred stock issuances in September 2011, the Company issued a warrant to purchase 129,310 shares of common stock to an investor who purchased Series A redeemable convertible preferred stock at an exercise price of $ 0.05 per share. The common stock warrant was exercised in December 2020 and is no longer outstanding

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock Warrants	9 Months Ended
	Sep. 30, 2021
Warrants And Rights Note Disclosure [Abstract]
Redeemable Convertible Preferred Stock Warrants	Note 9. Redeemable Convertible Preferred Stock Warrants 2019 Warrants In conjunction with the funding of Tranche 1 and Tranche 2 under the 2019 Term Loan, the Company issued the 2019 Initial Warrant to purchase 29,514 shares of its Series C redeemable convertible preferred stock (see Note 5). The 2019 Initial Warrant was immediately exercisable, at an exercise price per share of $ 9.49 , and expires 10 years from its date of issuance. Further, depending on the funding of the 2019 Term Loan Tranche 3, the Company was obligated to issue the 2019 Additional Warrant to the Lender to purchase up to 12,649 shares of Series C redeemable convertible preferred stock at the respective exercise price. The estimated fair value of the 2019 Warrants on the date of issuance was $ 0.2 million. As of the issuance date, the fair value of the 2019 Warrants was calculated using the Black-Scholes option-pricing model and was based on a term of 10 years , a risk-free interest rate of 2.99 %, expected volatility of 50.95 %, and 0 % expected dividend yield. At initial recognition, the 2019 Warrants were recorded at their estimated fair values and were subject to remeasurement at each balance sheet date, with changes in fair value recognized as a component of net income. On the completion of the IPO, the outstanding 2019 Initial Warrant was converted to 59,028 shares of common stock, which resulted in the re-classification of the convertible preferred stock warrant liability to additional paid-in capital. In August 2021, the 2019 Initial Warrant was net exercised and the Company issued 51,846 shares of common stock to Lender. As of December 31, 2020, the estimated fair value of the 2019 Warrants was $ 0.3 million. The fair value of the 2019 Warrants was calculated using the Black-Scholes option-pricing model with the following assumptions: July 19, December 31, 2021 (1) 2020 Expected term (in years) 0.04 8.1 – 8.5 Expected volatility 37.90 % 42.18 % – 42.63 % Risk-free interest rate 0.05 % 2.33 % – 2.49 % Dividend yield – – (1) Date the Company's registration statement (Form S-1) was declared effective 2020 Warrant In conjunction with entering into the 2020 Term Loan agreement, the Company issued the 2020 Warrant to purchase 300,000 shares of its Series F redeemable convertible preferred stock (see Note 5). The 2020 Warrant was immediately exercisable at an exercise price per share of $ 21.88 , and expires 10 years from its date of issuance. The estimated fair value of the 2020 Warrant on the date of issuance was $ 1.8 million. As of the issuance date, the fair value of the 2020 Warrant was calculated using a Multi-scenario Method with Discounts for Lack of Marketability for each class of security. At initial recognition, the 2020 Warrant was recorded at its estimated fair values and was subject to remeasurement at each balance sheet date, with changes in fair value recognized as a component of net income. On the completion of the IPO, the outstanding 2020 Warrant was converted to purchase 600,000 shares of common stock, which resulted in the re-classification of the convertible preferred stock warrant liability to additional paid-in capital. In August 2021, the 2020 Warrant was net exercised and the Company issued 431,708 shares of common stock. As of December 31, 2020, the estimated fair values of the 2020 Warrant was $ 6.0 million. The fair value of the redeemable convertible preferred stock warrants was determined using the following assumption: July 19, December 31, 2021 (1) 2020 Term (in years) 0.04 0.58 – 2.58 Expected volatility 37.90 % 55.9 % - 65.6 % Risk-free interest rate 0.05 % 0.08 % - 0.18 % (1) Date the Company's registration statement (Form S-1) was declared effective

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Common Stock	Note 10. Common Stock In connection with the Company’s IPO in July 2021, the Company’s certificate of incorporation was amended and restated to provide for 200,000,000 authorized shares of common stock with a par value of $ 0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $ 0.001 per share. The holders of common stock were also entitled to receive dividends whenever funds are legally available, when and if declared by the board of directors. As of September 30, 2021, no dividends have been declared to date. Each share of common stock is entitled to one vote. At September 30, 2021 and December 31, 2020, the Company had reserved common stock for future issuances as follows: September 30, December 31, 2021 2020 Conversion of Series A redeemable convertible preferred stock — 7,608,688 Conversion of Series B redeemable convertible preferred stock — 2,419,242 Conversion of Series C redeemable convertible preferred stock and warrants — 4,744,742 Conversion of Series D redeemable convertible preferred stock — 4,895,636 Conversion of Series E redeemable convertible preferred stock — 3,799,694 Conversion of Series F redeemable convertible preferred stock and warrants — 2,725,430 Exercise of options under stock plan 5,252,969 3,137,776 Issuance of options and restricted stock units under stock plan 5,331,595 451,670 Issuance of common stock under employee stock purchase plan 850,000 — 11,434,564 29,782,878

Equity Incentive Plan

Equity Incentive Plan	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans	Note 11. Equity Incentive Plans 2011 Stock Option Plan and 2021 Equity Incentive Plan In 2011, the Company established its 2011 stock option plan (the “2011 Plan”) that provided for the granting of stock options to employees and nonemployees of the Company. In July 2021, the Company’s Board of Directors and stockholders adopted and approved the 2021 Equity Incentive Plan, (the “2021 Plan”). The Company’s 2011 Stock Plan was terminated in connection with the IPO and no further grants will be made under the 2011 Plan from the date that the 2021 Plan became effective. Under the 2011 Plan, the Company had the ability to issue incentive stock options ("ISOs"), nonqualified stock options ("NSOs"), stock appreciation rights, dividend equivalent rights, restricted stock awards, and restricted stock unit awards. Options under the 2011 Plan could be granted for periods of up to 10 years. For incentive stock options granted to a grantee who, at the time the option is granted, owns stock representing more than 10% of the voting power of all classes of stock of the Company or any parent or subsidiary of the Company, the term of the incentive stock option may be granted for periods of up to five years. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. Options granted to new hires generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter; options granted as merit awards generally vest monthly over a four-year period. The Company reserved 5,200,000 shares of common stock for future issuance under the 2021 Plan. At September 30, 2021 and December 31, 2020, there were 5,331,595 shares and 451,670 shares, respectively, of common stock available for issuance under the 2021 Plan and 2011 Plan, respectively. Activity under the 2011 Plan and 2021 Plan is set forth below: Shares Number of Weighted-Average Exercise Price Weighted-Average Average Intrinsic Value Balances as of December 31, 2020 451,670 3,137,776 $ 0.94 6.8 $ 18,656 Additional shares reserved 7,260,000 Grants ( 2,487,203 ) 2,487,203 11.13 Forfeited/cancelled 107,128 ( 107,128 ) 2.89 Exercised/released ( 264,882 ) 1.01 Balances as of September 30, 2021 5,331,595 5,252,969 $ 5.72 7.6 $ 89,340 Vested and exercisable as of September 30, 2021 2,054,954 $ 1.46 5.2 $ 43,650 Vested and expected to vest as of September 30, 2021 5,222,969 $ 5.75 7.7 $ 88,662 The weighted-average grant-date fair values of options granted during the nine months ended September 30, 2021 and 2020 was $ 10.56 and $ 2.31 per share, respectively. The aggregate intrinsic value of options exercised were $ 4.2 million during the nine months ended September 30, 2021. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. As of September 30, 2021, the unrecognized stock-based compensation of unvested opti ons was $ 25.1 million, which is expected to be recognized over a weighted-average period of 3.5 years. Determination of fair value The Company estimated the fair value of stock options using the Black-Scholes option-pricing model. The fair value of stock options is recognized on a straight-line basis over the requisite service periods of the awards. The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Expected term (in years) 5.90 – 6.07 6.02 5.00 – 6.08 5.85 – 6.09 Expected volatility 60.3 % – 60.7 % 55.6 % 56.8 % – 60.8 % 48.3 % – 55.6 % Risk-free interest rate 0.95 % – 1.16 % 0.34 % 0.48 % – 1.16 % 0.33 % – 1.77 % Dividend yield – – – – Expected Term The expected term is calculated using the simplified method, which is available if there is insufficient historical data about exercise patterns and post vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant or for each vesting tranche for awards with graded vesting. The midpoint of the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting tranches, the time from grant until the midpoints for each of the tranches may be averaged to provide an overall expected term. Expected Volatility The Company used an average historical stock price volatility of a peer group of publicly traded companies to be representative of its expected future stock price volatility, as the Company did not have any trading history for its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size, and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term. Risk-Free Interest Rate The risk-free interest rate is based on the implied yield currently available on US Treasury zero-coupon issues with remaining terms equivalent to the expected term of a stock award. Expected Dividend Rate The Company has not paid, and does not anticipate paying, any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be 0 %. Restricted Stock Units RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred, and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date. In September 2021, the Company granted 23,800 RSUs at a grant-date fair value of $ 22.70 per share. There were no RSUs granted prior to September 2021. During the three months ended September 30, 2021, the Company recorded stock-based compensation of less than $ 0.1 million related to the RSUs. As of September 30, 2020, there was $ 0.5 million of total unrecognized compensation cost related to the RSUs that is expected to be recognized over a weighted-average period of 3.9 years. Stock Based Compensation The following is a summary of stock-based compensation expense by function (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of goods sold $ 22 $ 6 $ 46 $ 11 Research and development 169 28 307 51 Selling, general and administrative 1,708 131 2,754 229 Total stock-based compensation expense $ 1,899 $ 165 $ 3,107 $ 291 In July 2021, the Board of Directors and stockholders also adopted and approved the 2021 Employee Stock Purchase Plan (the “ESPP”). The Company reserved 850,000 shares of common stock for future issuance under the ESPP. As of September 30, 2021, no shares of common stock have been purchased under the ESPP.

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	Note 12. Net Loss per Share Attributable to Common Stockholders Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. As the Company reported a net loss for the three and nine months ended September 30, 2021 and 2020, basic net loss per share is the same as diluted net loss per share as the inclusion of potentially dilutive shares would have been antidilutive if included in the calculation. The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Numerator: Net loss attributable to common stockholders $ ( 17,169 ) $ ( 8,097 ) $ ( 47,024 ) $ ( 25,588 ) Denominator: Weighted-average shares of common stock 39,849,769 9,493,548 19,772,145 9,467,039 Net loss per share attributable to common $ ( 0.43 ) $ ( 0.85 ) $ ( 2.38 ) $ ( 2.70 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: September 30, 2021 2020 Series A redeemable convertible preferred stock — 3,804,344 Series B redeemable convertible preferred stock — 1,209,621 Series C redeemable convertible preferred stock — 2,342,857 Series D redeemable convertible preferred stock — 2,447,818 Series E redeemable convertible preferred stock — 1,899,847 Redeemable convertible preferred stock warrants — 42,163 Options to purchase common stock 5,229,169 3,152,862 Restricted stock units 23,800 — Total 5,252,969 14,899,512

Defined Contribution Plan

Defined Contribution Plan	9 Months Ended
	Sep. 30, 2021
Postemployment Benefits [Abstract]
Defined Contribution Plan	Note 13. Defined Contribution Plan The Company sponsors a defined contribution plan under Section 401(k) of the IRC of 1986, as amended, covering substantially all of its full-time US employees. Participating employees may contribute up to 100 % of their eligible compensation up to the annual Internal Revenue Service’s contribution limit. For the three and nine months ended September 30, 2021 and 2020, the Company did not match employee contributions.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	Note 14. Segment Information The Company has two reportable operating segments which are determined on the basis of product portfolio: Surgical Glaucoma and Dry Eye. The operating and reportable segments were determined based on how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), views and evaluates the Company’s operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on gross profit and gross profit margin. Surgical Glaucoma segment includes sales of the Company’s OMNI® Surgical System for use in minimally invasive glaucoma procedures. Dry Eye segment includes sales of the Company’s TearCare® System and related components. The following table summarizes select operating results information for each reportable segment (dollars in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue Surgical Glaucoma $ 12,446 $ 7,883 $ 32,573 $ 17,282 Dry Eye 655 768 1,698 1,367 Total 13,101 8,651 34,271 18,649 Cost of goods sold Surgical Glaucoma 1,621 1,946 5,252 4,968 Dry Eye 441 674 1,416 1,865 Total 2,062 2,620 6,668 6,833 Gross profit Surgical Glaucoma 10,825 5,937 27,321 12,314 Dry Eye 214 94 282 ( 498 ) Total 11,039 6,031 27,603 11,816 Operating expense 25,069 13,386 64,365 35,571 Loss from operations ( 14,030 ) ( 7,355 ) ( 36,762 ) ( 23,755 ) Interest income — 1 — 30 Interest expense ( 1,122 ) ( 538 ) ( 3,288 ) ( 1,639 ) Other income (expense), net ( 2,001 ) ( 197 ) ( 6,884 ) ( 179 ) Loss before income tax $ ( 17,153 ) $ ( 8,089 ) $ ( 46,934 ) $ ( 25,543 ) The Company does not allocate any income and expenses beyond revenue and cost of goods sold to the reportable operating segments in its reporting to the CODM. No asset information is provided for reportable operating segments because they are not reviewed by the CODM on segment basis. Substantially all of the Company’s revenue is generated from sales in the United States, and none of its property and equipment is located outside the United States.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events The Company evaluated subsequent events through November 10, 2021, the date on which the condensed consolidated financial statements were available for issuance.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) applicable to interim periods. The condensed consolidated financial statements, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the Company’s financial position and results of operations for the reported periods. These condensed consolidated financial statements have been prepared on a basis substantially consistent with, and should be read in conjunction with the audited financial statements for the year ended December 31, 2020 and notes thereto included in the prospectus, dated July 14, 2021, filed with the Securities and Exchange Commission ("SEC") in accordance with Rule 424(b) of the Securities Act on July 15, 2021 (the "Prospectus") in connection with our IPO that forms a part of the Company's Registration Statements on Form S-1 (File No. 333-257320), as filed with the SEC pursuant to Rule 424(b)(4) promulgated under the Securities Act. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with GAAP have been condensed or omitted from this report. The results of operations for any interim period are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period. The accompanying condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to inventory excess and obsolescence, the selection of useful lives of property and equipment, determination of the fair value of stock option grants, the fair value of the redeemable convertible preferred stock warrants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Company’s financial position and results of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, redeemable convertible preferred stock, short-term and long-term debt and redeemable convertible preferred stock warrant liability. The Company states accounts receivable, accounts payable, and accrued and other current liabilities at their carrying value, which approximates fair value due to the short time to the expected receipt or payment. The carrying amount of the Company’s debt approximates its fair value as the effective interest rate approximates market rates currently available to the Company. The redeemable convertible preferred stock warrant liability associated with the Company’s redeemable convertible preferred stock was carried at fair value based on unobservable market inputs. The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in July 2021. At that time, the preferred stock warrant liability was adjusted to fair value and reclassified to additional paid-in capital (see Note 3).
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s IPO, were deferred until completion of the IPO. As of December 31, 2020, deferred offering costs of $ 0.4 million were capitalized and are included in “Other noncurrent assets”. In July 2021, upon closing of the IPO, total deferred costs of $ 4.5 million were offset against the Company's IPO proceeds in additional paid in capital.
Accounting for Payroll Protection Program	Accounting for Payroll Protection Program In March 2020, Congress established the Paycheck Protection Program (“PPP”) to provide relief to small businesses during COVID-19 as part of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The legislation authorized the U.S. Treasury to use the Small Business Association’s (“SBA’s”) small business lending program to fund forgivable loans that qualifying businesses could spend to cover payroll, mortgage interest, rent, and utilities during the “Covered Period” defined as the 8-week period starting on the date the PPP loan proceeds are received. Upon meeting certain criteria as specified in the PPP program, the loans are eligible for partial or total forgiveness. In May 2020, the Company applied for and received a PPP loan for the amount $ 2.2 million from SBA. The PPP loan was forgiven in June 2021. GAAP does not contain authoritative accounting standards for forgivable loans provided by governmental entities to a for-profit entity. Absent authoritative accounting standards, interpretative guidance issued and commonly applied by financial statement preparers allows for the selection of accounting policies amongst acceptable alternatives. The Company determined it most appropriate to account for the PPP loan proceeds as an in-substance government grant by analogy to International Accounting Standards 20 (“IAS 20”) Accounting for Government Grants and Disclosure of Government Assistance . Under this guidance, a forgivable loan from government is treated as a government grant when there is reasonable assurance that the entity will meet the terms for forgiveness of the loan. While IAS 20 does not define “reasonable assurance”, this concept in practice is analogous to “probable” as defined in Financial Accounting Standards Board (“FASB”) ASC 450-20-20 under GAAP, which is the definition the Company applied to its expectations of PPP loan forgiveness. Under IAS 20, government grants are recognized in earnings on a systematic basis over the periods in which the Company recognizes costs for which the grant is intended to compensate (i.e. qualified expenses). Further, IAS 20 permits for the recognition in earnings either separately under a general heading such as other income, or as a reduction of the related expenses.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The guidance is effective for the Company beginning in the first quarter of 2023. The Company is evaluating the impact of adopting this guidance and does not expect to have a material impact on the Company’s financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , that simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation and modified the methodology for calculating income taxes in an interim period. It also clarifies and simplifies other aspects of the accounting for income taxes. The guidance is effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022 with early adoption permitted. The Company is evaluating the effect of this new guidance and does not expect it to have material impact on the Company’s financial statements. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The guidance also establishes (1) a general contract modification principle that entities can apply in other areas that may be affected by reference rate reform and (2) certain elective hedge accounting expedients. The amendment is effective for all entities through December 31, 2022. LIBOR is used to calculate the interest on borrowings under the Company’s term loan and revolving line of credit with MidCap Financial Services. The Company is evaluating the effect of this new guidance and does not expect it to have material impact on the Company’s financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Summary of Fair Value Measurement of Liabilities of Measured on Recurring Basis	The following table sets forth the fair value measurements of liabilities that are measured at fair value on a recurring basis as of December 31, 2020 (in thousands). As of September 30, 2021, there were no liabilities that are measured at fair value on a recurring basis. As of December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities: Redeemable convertible preferred stock warrants liabilities $ — $ — $ 2,112 $ 2,112 Total liabilities measured at fair value $ — $ — $ 2,112 $ 2,112
Summary of Changes in Level 3 Fair Value Instruments	A summary of the changes in the fair value of the Company’s Level 3 financial instruments for the three and nine months ended September 30, 2021 and 2020, is as follows (in thousands): Redeemable convertible preferred stock warrants liabilities Balance – December 31, 2020 $ 2,112 Change in fair value ( 555 ) Balance – March 31, 2021 1,557 Change in fair value 5,427 Balance – June 30, 2021 6,984 Change in fair value 1,989 Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO ( 8,973 ) Balance – September 30, 2021 $ — Redeemable convertible preferred stock warrants liabilities Balance – December 31, 2019 $ 236 Change in fair value ( 92 ) Balance – March 31, 2020 144 Change in fair value 73 Balance – June 30, 2020 217 Change in fair value 194 Balance – September 30, 2020 $ 411

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): As of September 30, As of December 31, 2021 2020 Tools and equipment $ 1,720 $ 1,523 Computer equipment and software 108 118 Furniture and fixtures 254 43 Leasehold improvements 29 30 Construction in process 393 298 2,504 2,012 Less: Accumulated depreciation ( 1,084 ) ( 743 ) Property and equipment, net $ 1,420 $ 1,269
Summary of Accrued and Other Current Liabilities	Accrued and other current liabilities consist of the following (in thousands): As of September 30, As of December 31, 2021 2020 Accrued expenses $ 2,569 $ 1,971 Current portion of lease liabilities 486 395 Short term interest payable 272 274 Other accrued liabilities 510 446 Total accrued and other current liabilities $ 3,837 $ 3,086
Summary of Other Noncurrent Liabilities	Other noncurrent liabilities consist of the following (in thousands): As of September 30, As of December 31, 2021 2020 Redeemable preferred stock warrants liabilities $ — $ 2,112 Long term interest payable 750 465 Noncurrent portion of lease liabilities 1,178 134 Other noncurrent liabilities 345 344 Total other noncurrent liabilities $ 2,273 $ 3,055

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-term and Short-term Debt	Long-term and short-term debt was as follows (in thousands): As of September 30, As of December 31, 2021 2020 Term Loan $ 35,000 $ 35,000 Total principal payments due 35,000 35,000 Less: debt discount related to warrant liability and issuance costs ( 2,514 ) ( 3,045 ) Total amounts outstanding 32,486 31,955 Less: Current portion — — Total accrued and other current liabilities $ 32,486 $ 31,955
Repayment Schedule Relating to the Company's Debt	The repayment schedule relating to the Company’s debt as of September 30, 2021, is as follows (in thousands): Amount 2021 (remainder) — 2022 ( 1,944 ) 2023 ( 11,667 ) 2024 ( 11,667 ) 2025 ( 9,722 ) Total repayments $ ( 35,000 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow	Operating lease expense and supplemental cash flow information related to operating leases for the three and nine months ended September 30, 2020 and 2021 were as follows (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Operating lease expense $ 175 $ 175 $ 528 $ 488 Cash paid for operating leases 131 173 484 517 New operating lease assets obtained in exchange for 1,514 — 1,537 —
Schedule of Aggregate Future Minimum Lease Payments	Aggregate future minimum lease payments at September 30, 2021 and December 31, 2020, under these noncancelable operating leases were as follows (in thousands): As of September 30, As of December 31, 2021 2020 2021 $ 170 $ 440 2022 691 66 2023 705 68 2024 462 29 Total future minimum lease payments $ 2,028 603 Less: imputed interest ( 364 ) ( 74 ) Present value of future minimum lease payments $ 1,664 529 Less: current portion of operating lease liability ( 486 ) ( 395 ) Operating lease liabilities - noncurrent $ 1,178 $ 134

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock (Table)	9 Months Ended
	Sep. 30, 2021
Redeemable Convertible Preferred Stock [Abstract]
Summary of Redeemable Convertible Preferred Stock Issued and Outstanding	The Company has the following redeemable convertible preferred stock issued and outstanding at December 31, 2020 (in thousands, except share and per share data): Shares Authorized Shares Issued and Outstanding Original Issuance Price Liquidation Amount Issuance Costs Carrying Value Series A 3,804,344 3,804,344 $ 1.38 $ 5,250 $ 9 $ 5,241 Series B 1,209,621 1,209,621 $ 5.79 7,000 106 6,894 Series C 2,372,371 2,342,857 $ 9.49 22,226 208 22,018 Series D 2,507,720 2,447,818 $ 12.56 30,750 647 30,103 Series E 1,921,902 1,899,847 $ 15.87 30,150 106 30,044 Series F 2,425,432 1,062,715 $ 21.88 23,250 219 23,031 14,241,390 12,767,202 $ 118,626 $ 1,295 $ 117,331 Immediately prior to the closing of the IPO, all then-outstanding shares of redeemable convertible preferred stock were converted into 25,534,404 shares of common stock, resulting in the reclassification of the related redeemable convertible preferred stock of $ 117.3 million to common stock and APIC. There was no redeemable convertible preferred stock outstanding as of September 30, 2021.

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
2019 Warrants
Class Of Warrant Or Right [Line Items]
Schedule of Fair Value of Warrants Calculated Using Black-Scholes Model	The fair value of the 2019 Warrants was calculated using the Black-Scholes option-pricing model with the following assumptions: July 19, December 31, 2021 (1) 2020 Expected term (in years) 0.04 8.1 – 8.5 Expected volatility 37.90 % 42.18 % – 42.63 % Risk-free interest rate 0.05 % 2.33 % – 2.49 % Dividend yield – – (1) Date the Company's registration statement (Form S-1) was declared effective
2020 Warrants
Class Of Warrant Or Right [Line Items]
Schedule of Fair Value of Warrants Calculated Using Black-Scholes Model	The fair value of the redeemable convertible preferred stock warrants was determined using the following assumption: July 19, December 31, 2021 (1) 2020 Term (in years) 0.04 0.58 – 2.58 Expected volatility 37.90 % 55.9 % - 65.6 % Risk-free interest rate 0.05 % 0.08 % - 0.18 % (1) Date the Company's registration statement (Form S-1) was declared effective

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Reserved Common Stock for Future Issuances	At September 30, 2021 and December 31, 2020, the Company had reserved common stock for future issuances as follows: September 30, December 31, 2021 2020 Conversion of Series A redeemable convertible preferred stock — 7,608,688 Conversion of Series B redeemable convertible preferred stock — 2,419,242 Conversion of Series C redeemable convertible preferred stock and warrants — 4,744,742 Conversion of Series D redeemable convertible preferred stock — 4,895,636 Conversion of Series E redeemable convertible preferred stock — 3,799,694 Conversion of Series F redeemable convertible preferred stock and warrants — 2,725,430 Exercise of options under stock plan 5,252,969 3,137,776 Issuance of options and restricted stock units under stock plan 5,331,595 451,670 Issuance of common stock under employee stock purchase plan 850,000 — 11,434,564 29,782,878

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	Activity under the 2011 Plan and 2021 Plan is set forth below: Shares Number of Weighted-Average Exercise Price Weighted-Average Average Intrinsic Value Balances as of December 31, 2020 451,670 3,137,776 $ 0.94 6.8 $ 18,656 Additional shares reserved 7,260,000 Grants ( 2,487,203 ) 2,487,203 11.13 Forfeited/cancelled 107,128 ( 107,128 ) 2.89 Exercised/released ( 264,882 ) 1.01 Balances as of September 30, 2021 5,331,595 5,252,969 $ 5.72 7.6 $ 89,340 Vested and exercisable as of September 30, 2021 2,054,954 $ 1.46 5.2 $ 43,650 Vested and expected to vest as of September 30, 2021 5,222,969 $ 5.75 7.7 $ 88,662
Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options	The fair value of stock options was estimated using the following weighted-average assumptions: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Expected term (in years) 5.90 – 6.07 6.02 5.00 – 6.08 5.85 – 6.09 Expected volatility 60.3 % – 60.7 % 55.6 % 56.8 % – 60.8 % 48.3 % – 55.6 % Risk-free interest rate 0.95 % – 1.16 % 0.34 % 0.48 % – 1.16 % 0.33 % – 1.77 % Dividend yield – – – –
Summary of Stock-Based Compensation Expense by Function	The following is a summary of stock-based compensation expense by function (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Cost of goods sold $ 22 $ 6 $ 46 $ 11 Research and development 169 28 307 51 Selling, general and administrative 1,708 131 2,754 229 Total stock-based compensation expense $ 1,899 $ 165 $ 3,107 $ 291

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Numerator: Net loss attributable to common stockholders $ ( 17,169 ) $ ( 8,097 ) $ ( 47,024 ) $ ( 25,588 ) Denominator: Weighted-average shares of common stock 39,849,769 9,493,548 19,772,145 9,467,039 Net loss per share attributable to common $ ( 0.43 ) $ ( 0.85 ) $ ( 2.38 ) $ ( 2.70 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: September 30, 2021 2020 Series A redeemable convertible preferred stock — 3,804,344 Series B redeemable convertible preferred stock — 1,209,621 Series C redeemable convertible preferred stock — 2,342,857 Series D redeemable convertible preferred stock — 2,447,818 Series E redeemable convertible preferred stock — 1,899,847 Redeemable convertible preferred stock warrants — 42,163 Options to purchase common stock 5,229,169 3,152,862 Restricted stock units 23,800 — Total 5,252,969 14,899,512

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following table summarizes select operating results information for each reportable segment (dollars in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue Surgical Glaucoma $ 12,446 $ 7,883 $ 32,573 $ 17,282 Dry Eye 655 768 1,698 1,367 Total 13,101 8,651 34,271 18,649 Cost of goods sold Surgical Glaucoma 1,621 1,946 5,252 4,968 Dry Eye 441 674 1,416 1,865 Total 2,062 2,620 6,668 6,833 Gross profit Surgical Glaucoma 10,825 5,937 27,321 12,314 Dry Eye 214 94 282 ( 498 ) Total 11,039 6,031 27,603 11,816 Operating expense 25,069 13,386 64,365 35,571 Loss from operations ( 14,030 ) ( 7,355 ) ( 36,762 ) ( 23,755 ) Interest income — 1 — 30 Interest expense ( 1,122 ) ( 538 ) ( 3,288 ) ( 1,639 ) Other income (expense), net ( 2,001 ) ( 197 ) ( 6,884 ) ( 179 ) Loss before income tax $ ( 17,153 ) $ ( 8,089 ) $ ( 46,934 ) $ ( 25,543 )

Company and Nature of Business

Company and Nature of Business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 19, 2021	Jul. 18, 2021	Jul. 07, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jul. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from initial public offering	$ 252,200									$ 256,680
Conversion of redeemable convertible preferred stock		25,534,404								25,534,404
Stock split			On July 7, 2021 the Company effected a 2-for-1 stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock.
Accumulated deficit				$ 137,065						$ 137,065		$ 90,041
Net loss				$ 17,169	$ 17,615	$ 12,240	$ 8,097	$ 8,316	$ 9,175	$ 47,024	$ 25,588
Common stock, shares authorized				200,000,000						200,000,000		21,831,000
Common stock, par value				$ 0.001						$ 0.001		$ 0.001
IPO
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of stock, price per share	$ 24
Underwriting discounts and commissions	$ 19,300
Estimated offering costs	$ 4,500											$ 400
Warrants to purchase common stock	659,028
Common stock, shares authorized													200,000,000
Common stock, par value													$ 0.001
Preferred stock, shares authorized													10,000,000
Preferred stock par value													$ 0.001
IPO | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock issued	10,000,000
Conversion of redeemable convertible preferred stock				25,534,404
Underwriters' Option | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock issued	1,500,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended
	May 31, 2020	Jul. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Deferred offering costs			$ 0.4
Deferred costs, current		$ 4.5
PPP Loan
Debt Instrument [Line Items]
Loan received	$ 2.2

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Fair Value Measurement Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Liabilities:
Total liabilities measured at fair value	$ 0	$ 2,112
Level 3
Liabilities:
Total liabilities measured at fair value		2,112
Redeemable Convertible Preferred Stock
Liabilities:
Total liabilities measured at fair value		2,112
Redeemable Convertible Preferred Stock | Level 3
Liabilities:
Total liabilities measured at fair value		$ 2,112

Fair value Measurement - Additi

Fair value Measurement - Additional Information (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities measured at fair value	$ 0	$ 2,112
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of outstanding debt	$ 32,500	$ 31,900

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes in Fair Value Level 3 Financial Liabilities (Details) - Level 3 - Redeemable Convertible Preferred Stock Warrants - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning Balance	$ 6,984	$ 1,557	$ 2,112	$ 217	$ 144	$ 236
Change in fair value	1,989	5,427	(555)	194	73	(92)
Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO	(8,973)
Ending Balance	$ 0	$ 6,984	$ 1,557	$ 411	$ 217	$ 144

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,504	$ 2,012
Less: Accumulated depreciation	(1,084)	(743)
Property and equipment, net	1,420	1,269
Tools and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,720	1,523
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	108	118
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	254	43
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	29	30
Construction In Process
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 393	$ 298

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Depreciation	$ 200	$ 100	$ 457	$ 418

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrued expenses	$ 2,569	$ 1,971
Current portion of lease liabilities	486	395
Short term interest payable	272	274
Other accrued liabilities	510	446
Total accrued and other current liabilities	$ 3,837	$ 3,086

Balance Sheet Components - Su_3

Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Redeemable preferred stock warrants liabilities	$ 0	$ 2,112
Long term interest payable	750	465
Noncurrent portion of lease liabilities	1,178	134
Other noncurrent liabilities	345	344
Total other noncurrent liabilities	$ 2,273	$ 3,055

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
		Aug. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 19, 2021	Dec. 31, 2020	Nov. 30, 2020	Jan. 31, 2019
Debt Instrument [Line Items]
Long-term Debt			$ 35,000,000		$ 35,000,000
IPO
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock							659,028
Proceeds from issuance of common stock					60,000,000
2019 Warrants
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock										59,028
Fair value of warrants					$ 200,000
2019 Warrants | Common Stock
Debt Instrument [Line Items]
Share of common stock issued upon warrant exercised		51,846
2020 Warrants
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock									600,000
Warrant term	[1]						14 days
2020 Warrants | Common Stock
Debt Instrument [Line Items]
Share of common stock issued upon warrant exercised		431,708
2020 Warrants | Minimum
Debt Instrument [Line Items]
Warrant term								6 months 29 days
2020 Warrants | Maximum
Debt Instrument [Line Items]
Warrant term								2 years 6 months 29 days
Series F Redeemable Convertible Preferred Stock | 2020 Warrants
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock									300,000
Warrant term									10 years
Class of warrant exercise price									$ 21.88
Senior Secured 2019 Term Loan
Debt Instrument [Line Items]
Debt instrument, term					4 years
Debt instrument payment terms					The 2019 Term Loan originally required 18 monthly interest-only payments, which began on January 31, 2019, followed by 30 equal monthly installments of principal, plus interest. The interest-only period was extended by an additional six months upon achievement of the Tranche Three Milestone.
Debt instrument, frequency of periodic payment					interest-only payments
Debt instrument interest payment term					18 months
Debt instrument principal and interest payment term					30 months
Debt instrument interest payment extended term					6 months
Debt instrument, effective interest rate			14.52%		14.52%
Interest expense, debt			$ 0	$ 500,000	$ 0	$ 1,600,000
Debt issuance costs			1,500,000		$ 1,500,000
Debt discount amortized term					4 years
Percentage of prepayment premium year one					3.00%
Percentage of prepayment premium year two					2.00%
Percentage of prepayment premium year three					1.00%
Percentage of final payment fee					5.00%
Debt Instrument, Covenant Description					The Company was subject to financial covenants related to minimum trailing revenue targets that began on January 1, 2019, and were tested on a monthly basis. Upon funding of only the Tranche One Loans, the Company had to achieve minimum net revenue of $7 million over a trailing 12-month period increasing to a maximum net revenue covenant of $35 million for the trailing 12-month period ending December 31, 2022, and thereafter. Upon funding of both the Tranche One Loans and Tranche Two Loans, the Company had to achieve minimum net revenue of $7 million over a trailing 12-month period increasing to a maximum net revenue covenant of $37.3 million for the 12-month period ending December 31, 2022, and thereafter. If Tranche Three Loans had been funded regardless of whether Tranche Two Loans had been funded, the Company would have been required to achieve minimum net revenue of $15 million over a trailing 12-month period increasing to a maximum net revenue covenant of $46.7 million for the 12-month period ending December 31, 2022, and thereafter.
Senior Secured 2019 Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable rate					6.75%
Senior Secured 2019 Term Loan | Tranche One Loans
Debt Instrument [Line Items]
Maximum borrowing capacity										$ 12,000,000
Debt instrument covenant minimum revenue			7,000,000		$ 7,000,000
Debt instrument covenant maximum revenue			35,000,000		35,000,000
Senior Secured 2019 Term Loan | Tranche Two Loans
Debt Instrument [Line Items]
Maximum borrowing capacity										2,000,000
Senior Secured 2019 Term Loan | Tranche Three Loans
Debt Instrument [Line Items]
Maximum borrowing capacity										6,000,000
Debt instrument covenant minimum revenue			15,000,000		15,000,000
Debt instrument covenant maximum revenue			$ 46,700,000		$ 46,700,000
Senior Secured 2019 Term Loan | Tranche Three Loans | Series C Redeemable Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock			12,649		12,649
Senior Secured 2019 Term Loan | Tranche One and Two Loans
Debt Instrument [Line Items]
Long-term Debt			$ 14,000,000		$ 14,000,000
Debt instrument covenant minimum revenue			7,000,000		7,000,000
Debt instrument covenant maximum revenue			$ 37,300,000		$ 37,300,000
Senior Secured 2019 Term Loan | Tranche One and Two Loans | Series C Redeemable Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock			29,514		29,514
Warrant term			10 years		10 years
Class of warrant exercise price			$ 9.49		$ 9.49
Senior Secured 2020 Term Loan
Debt Instrument [Line Items]
Debt instrument, term					5 years
Debt instrument payment terms					The 2020 Term Loan requires 24 monthly interest-only payments, which began on December 1, 2020, followed by 36 equal monthly installments of principal, plus interest.
Debt instrument interest payment term					24 months
Debt instrument principal and interest payment term					36 months
Debt instrument interest payment extended term					12 months
Debt instrument, effective interest rate			13.59%		13.59%
Interest expense, debt			$ 1,100,000	$ 0	$ 3,300,000	$ 0
Debt issuance costs			500,000		$ 500,000
Debt discount amortized term					5 years
Percentage of prepayment premium year one					3.00%
Percentage of prepayment premium year two					2.00%
Percentage of prepayment premium year three					1.00%
Percentage of final payment fee					6.00%
Accrued amount related accretion on maturity payments			800,000		$ 800,000			$ 500,000
Senior Secured 2020 Term Loan | Minimum
Debt Instrument [Line Items]
Debt instrument covenant minimum revenue			20,000,000		20,000,000
Senior Secured 2020 Term Loan | Maximum
Debt Instrument [Line Items]
Debt instrument covenant maximum revenue			$ 84,800,000		$ 84,800,000
Senior Secured 2020 Term Loan | Series F Redeemable Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants issued to purchase shares of convertible preferred stock			300,000		300,000
Warrant term			10 years		10 years
Class of warrant exercise price			$ 21.88		$ 21.88
Fair value of warrants					$ 1,800,000
Senior Secured 2020 Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable rate					7.00%
Senior Secured 2020 Term Loan | Tranche One Loans
Debt Instrument [Line Items]
Maximum borrowing capacity									$ 12,000,000
Senior Secured 2020 Term Loan | Tranche Two Loans
Debt Instrument [Line Items]
Maximum borrowing capacity									2,000,000
Senior Secured 2020 Term Loan | Tranche Three Loans
Debt Instrument [Line Items]
Maximum borrowing capacity									21,000,000
Long-term Debt									21,000,000
Revolver 2019
Debt Instrument [Line Items]
Line of credit facility, commitment fee description					An unused line fee of 0.5% was payable monthly based on the average unused balance and a collateral management fee of 0.5% was payable monthly based on the outstanding balance of the 2019 Revolver.
Line of credit facility, unused capacity, commitment fee percentage					0.50%
Line of credit facility collateral fees			0.50%		0.50%
Line of credit facility commitment fee amount					$ 10,000,000
Revolver 2019 | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable rate					4.25%
Revolving 2020
Debt Instrument [Line Items]
Line of credit facility, commitment fee description					An unused line fee of 0.5% is payable monthly based on the average unused balance and a collateral management fee of 0.5% is payable monthly based on the outstanding balance of the 2020 Revolver.
Line of credit facility, unused capacity, commitment fee percentage					0.50%
Line of credit facility collateral fees			0.50%		0.50%
Line of credit facility commitment fee amount					$ 15,000,000
Line of credit facility, current borrowing capacity			$ 5,000,000		$ 5,000,000
Revolving 2020 | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable rate					4.50%
Mid Cap Financial Services
Debt Instrument [Line Items]
Maximum borrowing capacity									40,000,000	25,000,000
Mid Cap Financial Services | Senior Secured 2019 Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity										20,000,000
Mid Cap Financial Services | Senior Secured 2020 Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity									35,000,000
Mid Cap Financial Services | Revolver 2019
Debt Instrument [Line Items]
Maximum borrowing capacity										$ 5,000,000
Mid Cap Financial Services | Revolving 2020
Debt Instrument [Line Items]
Maximum borrowing capacity									$ 5,000,000
[1]	Date the Company's registration statement (Form S-1) was declared effective

Debt - Schedule of Long-term an

Debt - Schedule of Long-term and Short-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal payments due	$ 35,000	$ 35,000
Less: debt discount related to warrant liability and issuance costs	(2,514)	(3,045)
Total amounts outstanding	32,486	31,955
Less: Current portion	0	0
Total accrued and other current liabilities	32,486	31,955
Term Loan
Debt Instrument [Line Items]
Principal payments due	$ 35,000	$ 35,000

Debt - Schedule Relating to the

Debt - Schedule Relating to the Company's Debt (Details) $ in Thousands	Sep. 30, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ (1,944)
2023	(11,667)
2024	(11,667)
2025	(9,722)
Total repayments	$ (35,000)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	Feb. 05, 2021USD ($)	Sep. 30, 2019ft²	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
Operating lease office space | ft²		10,823
Lease expiration date		Jul. 31, 2021
Lease commencement date	Aug. 1, 2021
Operating lease right-of-use assets	$ 1,500		$ 1,612		$ 1,612		$ 518
Lease, borrowing rate	13.59%
Operating leases, rent expense			$ 175	$ 175	$ 528	$ 488
Total base rent under lease agreement	$ 1,600
Operating lease, discount rate			16.40%		16.40%
Operating lease term	37 months		2 years 10 months 24 days		2 years 10 months 24 days

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Operating lease expense	$ 175	$ 175	$ 528	$ 488
Cash paid for operating leases	131	$ 173	484	$ 517
New operating lease assets obtained in exchange for operating lease liabilities	$ 1,514		$ 1,537

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
2021	$ 170	$ 440
2022	691	66
2023	705	68
2024	462	29
Total future minimum lease payments	2,028	603
Less: imputed interest	(364)	(74)
Present value of future minimum lease payments	1,664	529
Less: current portion of operating lease liability	(486)	(395)
Noncurrent portion of lease liabilities	$ 1,178	$ 134

Redeemable Convertible Prefer_5

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Shares Issued				12,767,202
Shares Outstanding				12,767,202
Series A
Class Of Stock [Line Items]
Shares Authorized				3,804,344
Shares Issued				3,804,344
Shares Outstanding				3,804,344
Original Issuance Price				$ 1.38
Liquidation Amount				$ 5,250
Issuance Costs				9
Carrying Value				$ 5,241
Series B
Class Of Stock [Line Items]
Shares Authorized				1,209,621
Shares Issued				1,209,621
Shares Outstanding				1,209,621
Original Issuance Price				$ 5.79
Liquidation Amount				$ 7,000
Issuance Costs				106
Carrying Value				$ 6,894
Series C
Class Of Stock [Line Items]
Shares Authorized				2,372,371
Shares Issued				2,342,857
Shares Outstanding				2,342,857
Original Issuance Price				$ 9.49
Liquidation Amount				$ 22,226
Issuance Costs				208
Carrying Value				$ 22,018
Series D
Class Of Stock [Line Items]
Shares Authorized				2,507,720
Shares Issued				2,447,818
Shares Outstanding				2,447,818
Original Issuance Price				$ 12.56
Liquidation Amount				$ 30,750
Issuance Costs				647
Carrying Value				$ 30,103
Series E
Class Of Stock [Line Items]
Shares Authorized				1,921,902
Shares Issued				1,899,847
Shares Outstanding				1,899,847
Original Issuance Price				$ 15.87
Liquidation Amount				$ 30,150
Issuance Costs				106
Carrying Value				$ 30,044
Series F
Class Of Stock [Line Items]
Shares Authorized				2,425,432
Shares Issued				1,062,715
Shares Outstanding				1,062,715
Original Issuance Price				$ 21.88
Liquidation Amount				$ 23,250
Issuance Costs				219
Carrying Value				$ 23,031
Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Shares Authorized	10,000,000			14,241,390
Shares Issued	0			12,767,202
Shares Outstanding	0	12,767,202	12,767,202	12,767,202	11,704,487	11,704,487	9,804,640
Liquidation Amount				$ 118,626
Issuance Costs				1,295
Carrying Value	$ 0	$ 117,331	$ 117,331	$ 117,331	$ 94,244	$ 94,311	$ 64,256

Redeemable Convertible Prefer_6

Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($) $ in Thousands	Jul. 18, 2021	Sep. 30, 2021
Class Of Stock [Line Items]
Stock issued upon conversion of redeemable convertible preferred shares (in shares)	25,534,404	25,534,404
Reclassification of the related redeemable convertible preferred stock		$ 117,300
Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock outstanding		$ 0

Common Stock Warrants - Additio

Common Stock Warrants - Additional Information (Details) - Series A Redeemable Convertible Preferred Stock - $ / shares	Sep. 30, 2021	Sep. 30, 2011
Class Of Stock [Line Items]
Warrants to purchase shares of stock		129,310
Class of warrant exercise price		$ 0.05
Warrant outstanding	0

Redeemable Convertible Prefer_7

Redeemable Convertible Preferred Stock Warrants - Additional Information (Details) $ / shares in Units, $ in Millions		1 Months Ended
		Aug. 31, 2021shares	Jul. 19, 2021		Dec. 31, 2020USD ($)	Nov. 30, 2020USD ($)$ / sharesshares	Nov. 30, 2019shares	Jan. 31, 2019USD ($)$ / sharesshares
2019 Warrants
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of stock								59,028
Warrants fair value | $					$ 0.3			$ 0.2
2019 Warrants | Common Stock
Class Of Warrant Or Right [Line Items]
Share of common stock issued upon warrant exercised		51,846
2019 Warrants | Measurement Input Expected Term
Class Of Warrant Or Right [Line Items]
Warrant term			14 days	[1]				10 years
2019 Warrants | Measurement Input Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.0005	[1]				0.0299
2019 Warrants | Measurement Input Price Volatility
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.3790	[1]				0.5095
2019 Warrants | Measurement Input Expected Dividend Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input								0
2020 Warrants
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of stock						600,000
Warrants fair value | $					$ 6	$ 1.8
Warrant term	[2]		14 days
2020 Warrants | Common Stock
Class Of Warrant Or Right [Line Items]
Share of common stock issued upon warrant exercised		431,708
2020 Warrants | Measurement Input Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	[2]		0.0005
2020 Warrants | Measurement Input Price Volatility
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	[2]		0.3790
Series C Redeemable Convertible Preferred Stock | 2019 Warrants | Funding of Tranche 1 and Tranche 2 under 2019 Term Loan
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of stock								29,514
Class of warrant exercise price | $ / shares								$ 9.49
Warrant term								10 years
Series C Redeemable Convertible Preferred Stock | 2019 Warrants | Funding of 2019 Term Loan Tranche 3
Class Of Warrant Or Right [Line Items]
Additional warrants issued expired							12,649
Series F Redeemable Convertible Preferred Stock | 2020 Warrants
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of stock						300,000
Class of warrant exercise price | $ / shares						$ 21.88
Warrant term						10 years
[1]	Date the Company's registration statement (Form S-1) was declared effective
[2]	Date the Company's registration statement (Form S-1) was declared effective

Redeemable Convertible Prefer_8

Redeemable Convertible Preferred Stock Warrants - Calculation Assumption of Fair Value of Warrants Using Black-Scholes Option Pricing Model (Details) - 2019 Warrants	Jul. 19, 2021	[1]	Dec. 31, 2020	Jan. 31, 2019
Measurement Input Expected Term
Class Of Warrant Or Right [Line Items]
Warrants term (in years)	14 days			10 years
Measurement Input Expected Term | Minimum
Class Of Warrant Or Right [Line Items]
Warrants term (in years)			8 years 1 month 6 days
Measurement Input Expected Term | Maximum
Class Of Warrant Or Right [Line Items]
Warrants term (in years)			8 years 6 months
Measurement Input Price Volatility
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	0.3790			0.5095
Measurement Input Price Volatility | Minimum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.4218
Measurement Input Price Volatility | Maximum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.4263
Measurement Input Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	0.0005			0.0299
Measurement Input Risk Free Interest Rate | Minimum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.0233
Measurement Input Risk Free Interest Rate | Maximum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.0249
Measurement Input Expected Dividend Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input				0
[1]	Date the Company's registration statement (Form S-1) was declared effective

Redeemable Convertible Prefer_9

Redeemable Convertible Preferred Stock Warrants - Assumption Used To Determined Redeemable Convertible Preferred Stock Fair Value (Details) - 2020 Warrants		Jul. 19, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Term (in years)	[1]	14 days
Minimum
Class Of Warrant Or Right [Line Items]
Term (in years)			6 months 29 days
Maximum
Class Of Warrant Or Right [Line Items]
Term (in years)			2 years 6 months 29 days
Measurement Input Price Volatility
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	[1]	0.3790
Measurement Input Price Volatility | Minimum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.559
Measurement Input Price Volatility | Maximum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.656
Measurement Input Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	[1]	0.0005
Measurement Input Risk Free Interest Rate | Minimum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.0008
Measurement Input Risk Free Interest Rate | Maximum
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0.0018
[1]	Date the Company's registration statement (Form S-1) was declared effective

Common Stock - Additional Infor

Common Stock - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021USD ($)Vote$ / sharesshares	Jul. 31, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized | shares	200,000,000		21,831,000
Common stock, par value | $ / shares	$ 0.001		$ 0.001
Dividends declared | $	$ 0
Number of votes entitled per share of common stock | Vote	1
IPO
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized | shares		200,000,000
Preferred stock, shares authorized | shares		10,000,000
Common stock, par value | $ / shares		$ 0.001
Preferred stock par value | $ / shares		$ 0.001

Common Stock - Reserved Common

Common Stock - Reserved Common Stock for Future Issuances (Details) - shares	Sep. 30, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	11,434,564	29,782,878
Series A Redeemable Convertible Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	0	7,608,688
Series B Redeemable Convertible Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	0	2,419,242
Series C Redeemable Convertible Preferred Stock and Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	0	4,744,742
Series D Redeemable Convertible Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	0	4,895,636
Series E Redeemable Convertible Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	0	3,799,694
Series F Redeemable Convertible Preferred Stock and Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	0	2,725,430
Exercise of Options under Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	5,252,969	3,137,776
Issuance of options and restricted stock units under stock plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	5,331,595	451,670
Issuance of common stock under employee stock purchase plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	850,000	0

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jul. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant-date fair values of options granted								$ 10.56	$ 2.31
Aggregate intrinsic value of options exercised								$ 4,200,000
Unrecognized stock-based compensation of unvested options	$ 25,100,000							$ 25,100,000
Weighted-average period expected to recognize								3 years 6 months
Dividend yield							0.00%
Common stock reserved for future issuance	11,434,564							11,434,564			29,782,878
Share of common stock purchased	$ 1,899,000	$ 931,000	$ 277,000	$ 165,000	$ 65,000	$ 61,000
Restricted Stock Units RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period								4 years
Unrecognized stock-based compensation of unvested options	500,000							$ 500,000
Weighted-average period expected to recognize								3 years 10 months 24 days
Number of Shares, Granted								23,800
Weighted-Average Exercise Price, Granted								$ 22.70
Maximum | Restricted Stock Units RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 100
2011 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for issuance											451,670
2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for issuance	5,331,595							5,331,595
Common stock reserved for future issuance										5,200,000
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance										850,000
Share of common stock purchased								$ 0

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Company stock Option Activity (Detail) - 2011 Plan and 2021 Plan $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Shares Available for Grant	5,331,595	451,670
Shares Available for Grant, Forfeited/cancelled	107,128
Shares Available for Grant	451,670
Shares Available for Grant, Granted	(2,487,203)
Shares Available for Grant, Additional shares reserved	7,260,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares	3,137,776
Number of Shares, Granted	2,487,203
Number of Shares, Forfeited/cancelled	(107,128)
Number of Shares, Exercised/released	(264,882)
Number of Shares	5,252,969	3,137,776
Number of Shares Vested and exercisable as of September 30, 2021	2,054,954
Number of Shares, Vested and expected to vest as of Septmeber 30, 2021	5,222,969
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price | $ / shares	$ 0.94
Weighted-Average Exercise Price, Granted | $ / shares	11.13
Weighted-Average Exercise Price, Forfeited/cancelled | $ / shares	2.89
Weighted-Average Exercise Price, Exercised/released | $ / shares	1.01
Weighted-Average Exercise Price | $ / shares	5.72	$ 0.94
Weighted-Average Exercise Price, Vested and exercisable as of September 30, 2021 | $ / shares	1.46
Weighted-Average Exercise Price, Expected to vest as of September 30, 2021 | $ / shares	$ 5.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term	7 years 7 months 6 days	6 years 9 months 18 days
Weighted average contractual term, vested and exercisable	5 years 2 months 12 days
Weighted average contractual term, vested and expected	7 years 8 months 12 days
Average Intrinsic Value | $	$ 89,340	$ 18,656
Average Intrinsic Value, Vested and exercisable as of September 30, 2021 | $	43,650
Average Intrinsic Value, Vested and expected as of September 30, 2021 | $	$ 88,662

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 7 days
Expected volatility		55.60%
Risk-free interest rate		0.34%
Dividend yield			0.00%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 25 days			6 years 29 days	6 years 1 month 2 days
Expected volatility	60.70%			60.80%	55.60%
Risk-free interest rate	1.16%			1.16%	1.77%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 10 months 24 days			5 years	5 years 10 months 6 days
Expected volatility	60.30%			56.80%	48.30%
Risk-free interest rate	0.95%			0.48%	0.33%

Equity Incentive Plans - Summ_3

Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,899	$ 165	$ 3,107	$ 291
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	22	6	46	11
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	169	28	307	51
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,708	$ 131	$ 2,754	$ 229

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss attributable to common stockholders	$ (17,169)	$ (17,615)	$ (12,240)	$ (8,097)	$ (8,316)	$ (9,175)	$ (47,024)	$ (25,588)
Denominator:
Weighted-average shares outstanding, basic and diluted	39,849,769			9,493,548			19,772,145	9,467,039
Net loss per share attributable to common stockholders, basic and diluted	$ (0.43)			$ (0.85)			$ (2.38)	$ (2.70)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Anti-dilutive securities excluded from computation of earnings per share	5,252,969	14,899,512
Series A Redeemable Convertible Preferred Stock
Anti-dilutive securities excluded from computation of earnings per share	0	3,804,344
Series B Redeemable Convertible Preferred Stock
Anti-dilutive securities excluded from computation of earnings per share	0	1,209,621
Series C Redeemable Convertible Preferred Stock
Anti-dilutive securities excluded from computation of earnings per share	0	2,342,857
Series D Redeemable Convertible Preferred Stock
Anti-dilutive securities excluded from computation of earnings per share	0	2,447,818
Series E Redeemable Convertible Preferred Stock
Anti-dilutive securities excluded from computation of earnings per share	0	1,899,847
Redeemable Convertible Preferred Stock Warrants
Anti-dilutive securities excluded from computation of earnings per share	0	42,163
Options to Purchase Common Stock
Anti-dilutive securities excluded from computation of earnings per share	5,229,169	3,152,862
Restricted Stock Units
Anti-dilutive securities excluded from computation of earnings per share	23,800	0

Defined Contribution Plan - Add

Defined Contribution Plan - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021
Postemployment Benefits [Abstract]
Defined contribution plan, maximum annual contributions per employee	100.00%

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021Segment
Segment Reporting [Abstract]
Number of Reportable Segments	2

Segment Information - Summary o

Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue
Revenue	$ 13,101	$ 8,651	$ 34,271	$ 18,649
Cost of goods sold
Cost of goods sold	2,062	2,620	6,668	6,833
Gross profit
Gross profit	11,039	6,031	27,603	11,816
Operating expense	(25,069)	(13,386)	(64,365)	(35,571)
Loss from operations	(14,030)	(7,355)	(36,762)	(23,755)
Interest income		1		30
Interest expense	(1,122)	(538)	(3,288)	(1,639)
Other expense, net	(2,001)	(197)	(6,884)	179
Loss before income tax	(17,153)	(8,089)	(46,934)	(25,543)
Surgical Glaucoma
Revenue
Revenue	12,446	7,883	32,573	17,282
Cost of goods sold
Cost of goods sold	1,621	1,946	5,252	4,968
Gross profit
Gross profit	10,825	5,937	27,321	12,314
Dry Eye
Revenue
Revenue	655	768	1,698	1,367
Cost of goods sold
Cost of goods sold	441	674	1,416	1,865
Gross profit
Gross profit	$ 214	$ 94	$ 282	$ (498)